Pancreatic Cancer Research

ResearcherMorgridge Institute for ResearchActive in the last 2 years

Bin Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0695-393X; OpenAlex author ID A5000636860. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
26
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers

Papers 9

  1. Polychromatic Polarization Microscopy Differentiates Collagen Fiber Signatures in Benign Pancreatic Tissue and Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.modpat.2025.100768↗
  2. TTPAL expression as a potential indicator of tumorigenesis and immunosuppression in pancreatic cancer: Evidence from experimental validation and bioinformatic … Co-author DOI 10.1016/j.prp.2025.156104↗
  3. Revealing splenectomy-driven microRNA hsa-7b-5p's role in pancreatic cancer progression. Co-author DOI 10.1016/j.isci.2024.109045↗
  4. Corrigendum: Systematic characterization of the clinical relevance of KPNA4 in pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fonc.2023.1282120↗
  5. Differentiation of pancreatic ductal adenocarcinoma and chronic pancreatitis using graph neural networks on histopathology and collagen fiber features. Co-author DOI 10.1016/j.jpi.2022.100158↗
  6. Systematic Characterization of the Clinical Relevance of KPNA4 in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2022.834728↗
  7. A genetic variant conferred high expression of CAV2 promotes pancreatic cancer progression and associates with poor prognosis. Co-author DOI 10.1016/j.ejca.2021.04.008↗
  8. A genetic variant in PIK3R1 is associated with pancreatic cancer survival in the Chinese population. Co-author DOI 10.1002/cam4.2228↗
  9. Identification and functional analysis of heterogeneous FOXP3+ Treg cell subpopulations in human pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.scib.2018.05.028↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kevin W. Eliceiri · 2 shared papers, 2022–2025 · strength 0.47
  2. Agnes G. Loeffler · 2 shared papers, 2022–2025 · strength 0.47
  3. Jingpiao Bao · 2 shared papers, 2022–2023 · strength 0.36
  4. Guoyong Hu · 2 shared papers, 2022–2023 · strength 0.36
  5. Mahsa Chitsaz · 1 shared paper, 2025 · strength 0.27
  6. Hui Liu · 1 shared paper, 2025 · strength 0.26
  7. Tao Tang · 1 shared paper, 2025 · strength 0.26
  8. Liangliang Wu · 1 shared paper, 2024 · strength 0.21
  9. Peng Jin · 1 shared paper, 2024 · strength 0.21
  10. Xiaona Wang · 1 shared paper, 2024 · strength 0.21
  11. Yuexiang Liang · 1 shared paper, 2024 · strength 0.21
  12. Bo Ni · 1 shared paper, 2024 · strength 0.21
  13. Yongjie Xie · 1 shared paper, 2024 · strength 0.21
  14. Ying Zhu · 2 shared papers, 2019–2021 · strength 0.17
  15. Jianbo Tian · 2 shared papers, 2019–2021 · strength 0.17
  16. Rong Zhong · 2 shared papers, 2019–2021 · strength 0.17
  17. Xiaoping Miao · 2 shared papers, 2019–2021 · strength 0.17
  18. Pingting Ying · 2 shared papers, 2019–2021 · strength 0.17
  19. Jiang Chang · 2 shared papers, 2019–2021 · strength 0.17
  20. Wenyu Liu · 1 shared paper, 2018 · strength 0.09
  21. Gang Y Jin · 1 shared paper, 2018 · strength 0.09
  22. Gang Yi · 1 shared paper, 2018 · strength 0.09
  23. Shiwei Guo · 1 shared paper, 2018 · strength 0.09
  24. Shufang Mei · 1 shared paper, 2019 · strength 0.07
  25. Juntao Ke · 1 shared paper, 2019 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.